Table 1.
Characteristics of haematopoietic stem cell transplantation recipients (n = 27).
| Age (years) | 6 (9.8) |
| Female gender | 14 (52) |
| Indication for HSCT | |
| PID | 9 (33) |
| SAA | 5 (19) |
| ALL | 5 (19) |
| AML | 2 (7) |
| MDS | 3 (11) |
| Other | 3 (11) |
| Donor type | |
| MRD | 4 (15) |
| MMRD | 8 (30) |
| MUD | 12 (44) |
| MMUD | 3 (11) |
| Graft source | |
| Bone marrow | 14 (52) |
| Mobilized peripheral blood | 13 (48) |
| Conditioning regimen | |
| Reduced intensity | 17 (63) |
| Myeloablative | 10 (37) |
| GVHD prophylaxis* | 25 (93) |
| In vivo: ATG/alemtuzumab | 14 (52) |
| Ex vivo: T-celldepletion (CD45RA/ TCRαβ) | 11 (41) |
Data are n (%) or median (interquartile range) where appropriate.
Abbreviations: HSCT, haematopoietic stem cell transplantation; PID, primary immunodeficiency; SAA, severe aplastic anemia; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; MRD, matched related donor; MMRD, mismatched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; GVHD, graft versus host disease; ATG, anti-thymocyte globulin.
*Two patients transplanted from HLA-identical siblings received neither ATG nor T-cell depletion.